Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative Dementia

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 257-266

  Nielsen, Henrietta M ^a   Palmqvist, Sebastian ^b   Minthon, Lennart ^a,b   Londos, Elisabet ^b   Wennström, Malin ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Dementia with Lewy bodies; Gender; Hyaluronic acid; Inflammation; Vascular changes

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYALURONIC ACID; LEWY BODY DISEASE; MALE; MIDDLE AGED; SEX CHARACTERISTICS;

EID: 84860276754     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107537     Document Type: Article

References (59)

1. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16(3): 271-8 (1995).
2. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12): 1863-72 (2005).
3. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41(4):479-86 (1991).
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131-44 (2010).
5. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22(6):799-809 (2001).
6. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 26(1): 27-35 (2007).
7. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69(16):1569-79 (2007).
8. Mackenzie IR. Activated microglia in dementia with Lewy bodies. Neurology 55(1):132-4 (2000).
9. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47(2):425-32 (1996).
10. de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Annals of the New York Academy of Sciences. [Review] 924:136-52 (2000).
11. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiology of aging. [Review] 21(2):153-60 (2000).
12. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230(2): 207-14 (1999).
13. Oberholzer A, Keel M, Zellweger R, Steckholzer U, Trentz O, Ertel W. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. J Trauma 48(5):932-7 (2000).
14. Schroder J, Kahlke V, Staubach KH, Zabel P, Stuber F. Gender differences in human sepsis. Arch Surg 133(11):1200-5 (1998).
15. Wichmann MW, Muller C, Meyer G, Adam M, Angele MK, Eisenmenger SJ, et al. Different immune responses to abdominal surgery in men and women. Langenbecks Arch Surg 387(11-12): 397-401 (2003).
16. Lockshin MD. Sex differences in autoimmune disease. Lupus 15(11):753-6 (2006).
17. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2(9):777-80 (2001).
18. Perez-Lopez FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci. [Research Support, Non-U.S. Gov't Review]. 17(6): 511-31 (2010).
19. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 53(9):1992-7 (1999).
20. Azad NA, Al Bugami M, Loy-English I. Gender differences in dementia risk factors. Gend Med 4(2):120-9 (2007).
21. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 55(9): 809-15 (1998).
22. Wattmo C, Wallin AK, Londos E, Minthon L. Predictors of longterm cognitive outcome in Alzheimer's disease. Alzheimer's research & therapy. 3(4): 23 (2011).
23. MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Alzheimer Res Ther International journal of geriatric psychiatry. [Clinical Trial Research Support, Non-U.S. Gov't] 13(9):625-30 (1998).
24. Jenkins HG, Bachelard HS. Glycosaminoglycans in cortical autopsy samples from Alzheimer brain. J Neurochem 51(5):1641-5 (1998).
25. Shimizu H, Sato S, Ohishi H, Mori O, Mori T, Ohami H. [Proteoglycans in senile dementia of Alzheimer's type]. Nippon Ronen Igakkai Zasshi 34(6): 461-7 (1997).
26. Dityatev A, Fellin T. Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol 4(3): 235-47 (2008).
27. Bignami A, Hosley M, Dahl D. Hyaluronic acid and hyaluronic acid-binding proteins in brain extracellular matrix. Anat Embryol (Berl.). 188(5): 419-33 (1993).
28. Laurent TC, Fraser JR. Hyaluronan. FASEB J. 6(7): 2397-404 (1992).
29. Siegelman MH, DeGrendele HC, Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J Leukoc Biol 66(2): 315-21 (1999).
30. Genasetti A, Vigetti D, Viola M, Karousou E, Moretto P, Rizzi M, et al. Hyaluronan and human endothelial cell behavior. Connect Tissue Res 49(3):120-3 (2008).
31. Karangelis DE, Kanakis I, Asimakopoulou AP, Karousou E, Passi A, Theocharis AD, et al. Glycosaminoglycans as key molecules in atherosclerosis: the role of versican and hyaluronan. Curr Med Chem 17(33): 4018-26 (2010).
32. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. [Research Support, Non-U.S. Gov't] 7(3):263-9 (2011).
33. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113-24 (1996).
34. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-98 (1975).
35. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 33(2):129-33 (1999).
36. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3(2): 201-3 (1992).
37. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem 78:147-76 (2009).
38. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiological reviews. [Research Support, N.I.H., Extramural Review] 91(1):221-64 (2011).
39. Cotran RS, Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol Biol (Paris). 46(3): 164-70 (1988).
40. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 11(4):411-23 (2005).
41. Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front Neuroendocrinol 29(4): 507-19 (2008).
42. Tuomikoski P, Aittomaki K, Mikkola TS, Ropponen A, Ylikorkala O. Effect of oral and transdermal hormone therapy on hyaluronic acid in women with and without a history of intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol 198(4): 375 e1-5 (2008).
43. Sunil N, Srinivasan N, Aruldhas MM, Govindarajulu P. Impact of oestradiol and progesterone on the glycosaminoglycans and their depolymerizing enzymes of the rat mammary gland. Acta Physiol Scand 168(3): 385-92 (2000).
44. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol 4(6): 371-8 (2003).
45. de Deus JM, Girao MJ, Sartori MG, Baracat EC, Rodrigues de Lima G, Nader HB, et al. Glycosaminoglycan profile in bladder and urethra of castrated rats treated with estrogen, progestogen, and raloxifene. Am J Obstet Gynecol 189(6):1654-9 (2003).
46. Bollyky PL, Falk BA, Wu RP, Buckner JH, Wight TN, Nepom GT. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J Leukoc Biol 86(3): 567-72 (2009).
47. Miyata S, Nishimura Y, Nakashima T. Perineuronal nets protect against amyloid beta-protein neurotoxicity in cultured cortical neurons. Brain Res 1150: 200-6 (2007).
48. Morawski M, Bruckner MK, Riederer P, Bruckner G, Arendt T. Perineuronal nets potentially protect against oxidative stress. Exp Neurol 188(2): 309-15 (2004).
49. Genedani S, Agnati LF, Leo G, Buzzega D, Maccari F, Carone C, et al. beta-Amyloid fibrillation and/or hyperhomocysteinemia modify striatal patterns of hyaluronic acid and dermatan sulfate: Possible role in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 7(2):150-7 (2010).
50. Morawski M, Pavlica S, Seeger G, Grosche J, Kouznetsova E, Schliebs R, et al. Perineuronal nets are largely unaffected in Alzheimer model Tg2576 mice. Neurobiology of aging. [Comparative Study Research Support, Non-U.S. Gov't]. 31(7): 1254-6 (2010).
51. Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiology of aging. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] 22(6): 931-6 (2001).
52. Akiyama H, Tooyama I, Kawamata T, Ikeda K, McGeer PL. Morphological diversities of CD44 positive astrocytes in the cerebral cortex of normal subjects and patients with Alzheimer's disease. Brain Res 632(1-2): 249-59 (1993).
53. Al Qteishat A, Gaffney JJ, Krupinski J, Slevin M. Hyaluronan expression following middle cerebral artery occlusion in the rat. Neuroreport 17(11):1111-4 (2006).
54. Al'Qteishat A, Gaffney J, Krupinski J, Rubio F, West D, Kumar S, et al. Changes in hyaluronan production and metabolism following ischaemic stroke in man. Brain 129(Pt 8):2158-76 (2006).
55. Laurent UB, Laurent TC, Hellsing LK, Persson L, Hartman M, Lilja K. Hyaluronan in human cerebrospinal fluid. Acta Neurol Scand 94(3):194-206 (1996).
56. Ewers M, Mielke MM, Hampel H. Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Experimental gerontology. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review] 45(1):75-9 (2010).
57. Jung EM, Kwon O, Kwon KS, Cho YS, Rhee SK, Min JK, et al. Evidences for correlation between the reduced VCAM-1 expression and hyaluronan synthesis during cellular senescence of human mesenchymal stem cells. Biochem Biophys Res Commun. 404(1): 463-9 (2011).
58. Karatay S, Kiziltunc A, Yildirim K, Karanfil RC, Senel K. Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis. Ann Clin Lab Sci 34(3):330-5 (2004).
59. Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin 25(3): 741-60 (2007)vii.